Although ERTs have been highly beneficial to patients with these diseases, the ineffective correction of neurological, ocular and skeletal disease manifestations remains a major drawback of current therapies dependent upon MMR- and M6PR-dependent delivery. This evidence concerns the gene MRC1 and bone disorder.